Biological Effects in Cancer Cells of Mono- and Bidentate Conjugation of Cisplatin on PAMAM Dendrimers: A Comparative Study

Overview

Journal Pharmaceutics

Publisher MDPI

Date 2023 Feb 25

PMID 36840012

Authors

Claudia Camacho

Dina Maciel

Helena Tomas

Joao Rodrigues

Affiliations

Soon will be listed here.

Abstract

Cisplatin (-diamminedichloroplatinum(II)) is a potent chemotherapeutic agent commonly used to treat cancer. However, its use also leads to serious side effects, such as nephrotoxicity, ototoxicity, and cardiotoxicity, which limit the dose that can be safely administered to patients. To minimize these problems, dendrimers may be used as carriers for cisplatin through the coordination of their terminal functional groups to platinum. Here, cisplatin was conjugated to half-generation anionic PAMAM dendrimers in mono- and bidentate forms, and their biological effects were assessed in vitro. After preparation and characterization of the metallodendrimers, their cytotoxicity was evaluated against several cancer cell lines (A2780, A2780cisR, MCF-7, and CACO-2 cells) and a non-cancer cell line (BJ cells). The results showed that all the metallodendrimers were cytotoxic and that the cytotoxicity level depended on the cell line and the type of coordination mode (mono- or bidentate). Although, in this study, a correlation between dendrimer generation (number of carried metallic fragments) and cytotoxicity could not be completely established, the monodentate coordination form of cisplatin resulted in lower IC values, thus revealing a more accessible cisplatin release from the dendritic scaffold. Moreover, most of the metallodendrimers were more potent than the cisplatin, especially for the A2780 and A2780cisR cell lines, which showed higher selectivity than for non-cancer cells (BJ cells). The monodentate G0.5COO(Pt(NH)Cl) and G2.5COO(Pt(NH)Cl) metallodendrimers, as well as the bidentate G2.5COO(Pt(NH)) metallodendrimer, were even more active towards the cisplatin-resistant cell line (A2780cisR cells) than the correspondent cisplatin-sensitive one (A2780 cells). Finally, the effect of the metallodendrimers on the hemolysis of human erythrocytes was neglectable, and metallodendrimers' interaction with calf thymus DNA seemed to be stronger than that of free cisplatin.

References

Badisa R, Darling-Reed S, Joseph P, Cooperwood J, Latinwo L, Goodman C . Selective cytotoxic activities of two novel synthetic drugs on human breast carcinoma MCF-7 cells. Anticancer Res. 2009; 29(8):2993-6. PMC: 2885965. View

Johnstone T, Wilson J, Lippard S . Monofunctional and higher-valent platinum anticancer agents. Inorg Chem. 2013; 52(21):12234-49. PMC: 3818431. DOI: 10.1021/ic400538c. View

Sirajuddin M, Ali S, Badshah A . Drug-DNA interactions and their study by UV-Visible, fluorescence spectroscopies and cyclic voltametry. J Photochem Photobiol B. 2013; 124:1-19. DOI: 10.1016/j.jphotobiol.2013.03.013. View

Medina S, El-Sayed M . Dendrimers as carriers for delivery of chemotherapeutic agents. Chem Rev. 2009; 109(7):3141-57. DOI: 10.1021/cr900174j. View

Li X, Naeem A, Xiao S, Hu L, Zhang J, Zheng Q . Safety Challenges and Application Strategies for the Use of Dendrimers in Medicine. Pharmaceutics. 2022; 14(6). PMC: 9230513. DOI: 10.3390/pharmaceutics14061292. View

Pisani M, Wheate N, Keene F, Aldrich-Wright J, Collins J . Anionic PAMAM dendrimers as drug delivery vehicles for transition metal-based anticancer drugs. J Inorg Biochem. 2009; 103(3):373-80. DOI: 10.1016/j.jinorgbio.2008.11.014. View

Goncalves M, Castro R, Rodrigues J, Tomas H . The effect of PAMAM dendrimers on mesenchymal stem cell viability and differentiation. Curr Med Chem. 2012; 19(29):4969-75. DOI: 10.2174/0929867311209024969. View

Allison M, Carames-Mendez P, Pask C, Phillips R, Lord R, McGowan P . Bis(bipyridine)ruthenium(II) Ferrocenyl β-Diketonate Complexes: Exhibiting Nanomolar Potency against Human Cancer Cell Lines. Chemistry. 2020; 27(11):3737-3744. DOI: 10.1002/chem.202004024. View

Haririan I, Alavidjeh M, Khorramizadeh M, Shafiee Ardestani M, Ghane Z, Namazi H . Anionic linear-globular dendrimer-cis-platinum (II) conjugates promote cytotoxicity in vitro against different cancer cell lines. Int J Nanomedicine. 2010; 5:63-75. PMC: 2819903. DOI: 10.2147/ijn.s8595. View

10.

Johnstone T, Suntharalingam K, Lippard S . Third row transition metals for the treatment of cancer. Philos Trans A Math Phys Eng Sci. 2015; 373(2037). PMC: 4342973. DOI: 10.1098/rsta.2014.0185. View

11.

Farhat F, Temraz S, Kattan J, Ibrahim K, Bitar N, Haddad N . A phase II study of lipoplatin (liposomal cisplatin)/vinorelbine combination in HER-2/neu-negative metastatic breast cancer. Clin Breast Cancer. 2011; 11(6):384-9. DOI: 10.1016/j.clbc.2011.08.005. View

12.

Casagrande N, Celegato M, Borghese C, Mongiat M, Colombatti A, Aldinucci D . Preclinical activity of the liposomal cisplatin lipoplatin in ovarian cancer. Clin Cancer Res. 2014; 20(21):5496-506. DOI: 10.1158/1078-0432.CCR-14-0713. View

13.

Rottenberg S, Disler C, Perego P . The rediscovery of platinum-based cancer therapy. Nat Rev Cancer. 2020; 21(1):37-50. DOI: 10.1038/s41568-020-00308-y. View

14.

Maciel D, Guerrero-Beltran C, Cena-Diez R, Tomas H, Munoz-Fernandez M, Rodrigues J . New anionic poly(alkylideneamine) dendrimers as microbicide agents against HIV-1 infection. Nanoscale. 2019; 11(19):9679-9690. DOI: 10.1039/c9nr00303g. View

15.

Mjos K, Orvig C . Metallodrugs in medicinal inorganic chemistry. Chem Rev. 2014; 114(8):4540-63. DOI: 10.1021/cr400460s. View

16.

Ghosh S . Cisplatin: The first metal based anticancer drug. Bioorg Chem. 2019; 88:102925. DOI: 10.1016/j.bioorg.2019.102925. View

17.

Camacho C, Tomas H, Rodrigues J . Use of Half-Generation PAMAM Dendrimers (G0.5-G3.5) with Carboxylate End-Groups to Improve the DACHPtCl and 5-FU Efficacy as Anticancer Drugs. Molecules. 2021; 26(10). PMC: 8156256. DOI: 10.3390/molecules26102924. View

18.

Zahednezhad F, Zakeri-Milani P, Shahbazi Mojarrad J, Valizadeh H . The latest advances of cisplatin liposomal formulations: essentials for preparation and analysis. Expert Opin Drug Deliv. 2020; 17(4):523-541. DOI: 10.1080/17425247.2020.1737672. View

19.

Maciel D, Nunes N, Santos F, Fan Y, Li G, Shen M . New insights into ruthenium(II) metallodendrimers as anticancer drug nanocarriers: from synthesis to preclinic behaviour. J Mater Chem B. 2022; 10(43):8945-8959. DOI: 10.1039/d2tb01280d. View

20.

El Kazzouli S, El Brahmi N, Mignani S, Bousmina M, Zablocka M, Majoral J . From metallodrugs to metallodendrimers for nanotherapy in oncology: a concise overview. Curr Med Chem. 2012; 19(29):4995-5010. DOI: 10.2174/0929867311209024995. View